Astec LifeSciences
NSE: ASTEC · ISIN INE563J01010 · Basic Materials
₹527.20−40.10 (−7.07%)
Monday 9 November, 15:29 IST. Delayed. Source: Yahoo Finance.
Price chart
₹527.20 −40.10 (−7.07%) today
The day
- Previous close
- ₹567.30
- Open
- ₹563.10
- Day high
- ₹577.00
- Day low
- ₹518.80
Listed on NSE since 25 November 2009.
Key numbers
- Market value
- ₹1,174.72 Cr
- EPS (trailing)
- ₹-35.71
- Price to book
- 3.51
- Dividend yield
- 0.00%
- Return on equity
- -21.2%
- Debt to equity
- 0.99
- Profit margin
- -18.1%
- Beta
- 0.28
- Volume today
- 5.07 L
- Average volume
- 2.31 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹628.17 Cr | ₹25.56 Cr |
| FY24 | ₹457.70 Cr | ₹-46.93 Cr |
| FY25 | ₹378.15 Cr | ₹-134.75 Cr |
| FY26 | ₹445.72 Cr | ₹-80.92 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹72 Cr | ₹-37 Cr | – |
| Q1 FY27Apr–Jun 2026 | ₹84 Cr | ₹-19 Cr | – |
| Q4 FY26Jan–Mar 2026Audited | ₹159 Cr | ₹-8 Cr | – |
| Q3 FY26Oct–Dec 2025 | ₹125 Cr | ₹-16 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹74 Cr | ₹-24 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹91 Cr | ₹-33 Cr | – |
Source: Astec LifeSciences’s results filed with NSE, consolidated (the whole group). Net profit is the share of Astec LifeSciences’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹404 Cr | ₹424 Cr |
| Investments | ₹53,000 | ₹53,000 |
| Inventories | ₹171 Cr | ₹138 Cr |
| Owed by customers | ₹108 Cr | ₹248 Cr |
| Cash and equivalents | ₹14.61 L | ₹10 Cr |
| Total assets | ₹794 Cr | ₹942 Cr |
| Borrowings | ₹331 Cr | ₹449 Cr |
| Total liabilities | ₹459 Cr | ₹551 Cr |
| Shareholders’ equity | ₹335 Cr | ₹391 Cr |
Source: Astec LifeSciences’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Astec LifeSciences
Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maize, as well as grains, such as barley, rice, and wheat; post-harvest drench; and food additive and wood preservatives. It also provides herbicides, insecticides, and agrochemical intermediates. The company also exports its products. Further, it offers contract development and manufacturing operations. The company was incorporated in 1994 and is based in Mumbai, India. Astec LifeSciences Limited operates as a subsidiary of Godrej Agrovet Limited.
- Industry
- Agricultural Inputs
- Based in
- Mumbai
- Employees
- 471
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Astec LifeSciences in the last day or two.
Dividends and corporate actions
All companies- Rights 1:7 @ Premium Rs 880/-
Right · ex-date 4 July 2025
- Annual General Meeting
Action · ex-date 23 July 2024
- Annual General Meeting/Dividend - Rs 1.50 Per Share
Dividend · ex-date 21 July 2023
- Annual General Meeting/Dividend - Rs 1.50 Per Share
Dividend · ex-date 19 July 2022
- Annual General Meeting/Dividend - Rs 1.50 Per Share
Dividend · ex-date 22 July 2021
- Annual General Meeting/Dividend - Rs 1.50 Per Share
Dividend · ex-date 16 July 2020
- Annual General Meeting/ Dividend - Rs 1.50 Per Share
Dividend · ex-date 18 July 2019
- Annual General Meeting/Dividend- Rs 1.50 Per Share
Dividend · ex-date 19 July 2018
Source: NSE. Latest first, 8 of 16.
Information only, not investment advice. Prices are delayed.